文献速递骨质疏松与代谢性骨病骨肿瘤

他莫昔芬悖论:辅助他莫昔芬对绝经前后乳腺癌女性骨折风险的影响

The tamoxifen paradox-influence of adjuvant tamoxifen on fracture risk in pre- and postmenopausal women with breast cancer.
PubMed 文献 · Osteoporos Int · 2018-07-21

18至50岁接受他莫昔芬治疗者骨折累积发生率为6.3%,对照组为3.6%(p<0.001),骨折风险升高75%(HR 1.75;95%CI 1.25-2.48);55至90岁者两组的累积发生率分别为10.1%与9.3%(p=0.740),差异无统计学意义(HR 0.97;95%CI 0.81-1.16)。作者结论为:与健康对照相比,接受他莫昔芬治疗的绝经前乳腺癌女性骨折风险增加,而绝经后女性接受他莫昔芬未见任何风险降低。

要点

  • 18至50岁接受他莫昔芬治疗的乳腺癌女性骨折风险高于健康对照(HR 1.75;95%CI 1.25-2.48)。
  • 55至90岁接受他莫昔芬者与对照的骨折风险无显著差异(HR 0.97;95%CI 0.81-1.16)。
  • 作者指出他莫昔芬不降低骨折风险,绝经前乳腺癌女性治疗开始后需密切监测以预防骨丢失。

核心结论

  • 他莫昔芬不降低骨折风险;与健康对照相比,接受他莫昔芬治疗的绝经前乳腺癌女性骨折风险增加,绝经后女性接受他莫昔芬未见风险降低。

主要发现

  • 18至50岁接受他莫昔芬治疗者(n=3634)骨折累积发生率为6.3%,对照组为3.6%(p<0.001),骨折风险为健康对照的1.75倍(HR 1.75;95%CI 1.25-2.48)。
  • 55至90岁接受他莫昔芬治疗者(n=7406)骨折累积发生率为10.1%,对照组为9.3%(p=0.740),两组间无显著差异(HR 0.97;95%CI 0.81-1.16)。

临床怎么用

  • 作者指出,绝经前乳腺癌女性在接受他莫昔芬治疗开始后需密切监测以预防骨丢失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Our data demonstrate that tamoxifen does not reduce fracture risk. Close surveillance is necessary to prevent bone loss in premenopausal women with breast cancer upon treatment initiation. INTRODUCTION: Endocrine treatment of breast cancer may interfere with bone turnover and influence fracture risk. METHODS: Out of a cohort of almost 5 million patients in total, we identified 5520 women between 18 and 90 years of age with breast cancer receiving tamoxifen, matched them with 5520 healthy controls using the Disease Analyzer Database, and investigated the fracture risk. RESULTS: We found a cumulative incidence of fractures of 6.3% in patients aged between 18 and 50 years (n = 3634) treated with tamoxifen versus a cumulative incidence of 3.6% in the control group (p < 0.001). As such, the risk of fracture was 75% higher for patients receiving tamoxifen than that for healthy controls (HR 1.75; 95% CI 1.25-2.48). With regard to patients aged between 55 and 90 years (n = 7406), the cumulative incidence of fractures in patients treated with tamoxifen was 10.1% compared to 9.3% in the control group (p = 0.740), i.e., there was no significant difference between the two groups (HR 0.97; 95% CI 0.81-1.16). CONCLUSIONS: Compared to healthy controls, premenopausal women with breast cancer treated with tamoxifen showed an increased risk of fracture, while postmenopausal women on tamoxifen did not show any risk reduction.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Kyvernitakis I, Kostev K, Hadji P, et al. The tamoxifen paradox-influence of adjuvant tamoxifen on fracture risk in pre- and postmenopausal women with breast cancer. Osteoporos Int. 2018. PMID: 30032359. doi:10.1007/s00198-018-4642-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。